Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.77 -5.9%	$2.43	$1.77 ▼ $4.98	$177.73M	1.49	328,731 shs	230,400 shs
BLUE bluebird bio	$4.89 -2.8%	$5.35	$3.56 ▼ $28.60	$47.54M	0.76	381,770 shs	289,834 shs
CRGX CARGO Therapeutics	$4.10 -3.1%	$4.84	$3.00 ▼ $25.45	$188.81M	1.65	457,770 shs	297,726 shs
TVGN Tevogen Bio	$1.00 -6.5%	$1.32	$0.26 ▼ $4.78	$175.05M	-1.07	5.08 million shs	527,713 shs

7 Top Nuclear Stocks To Buy Now

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+4.74%	-5.53%	-21.67%	-34.04%	-30.37%
BLUE bluebird bio	-4.19%	+34.13%	+29.64%	-42.12%	-79.21%
CRGX CARGO Therapeutics	+2.67%	+4.70%	+14.95%	-71.89%	-79.77%
TVGN Tevogen Bio	-1.83%	-8.55%	-9.32%	+0.94%	-63.73%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.4921 of 5 stars	3.5	2.0	2.6	0.8	1.3
BLUE bluebird bio	2.9775 of 5 stars	3.1	3.0	2.9	2.5	1.3
CRGX CARGO Therapeutics	3.137 of 5 stars	3.9	0.0	2.9	1.7	1.3
TVGN Tevogen Bio	3.1253 of 5 stars	3.5	2.0	1.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	577.97% Upside
BLUE bluebird bio	2.25	Hold	$44.60	812.07% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	265.85% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	610.00% Upside

Current Analyst Ratings Breakdown

Latest BLUE, TVGN, ACIU, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/31/2025	BLUE bluebird bio	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $8.00
3/14/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/11/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
2/24/2025	BLUE bluebird bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $5.00
2/24/2025	BLUE bluebird bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
2/21/2025	BLUE bluebird bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
1/30/2025	CRGX CARGO Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/30/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$32.00 ➝ $3.00
1/30/2025	CRGX CARGO Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$34.00 ➝ $4.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$27.31M	6.51	N/A	N/A	$2.12 per share	0.83
BLUE bluebird bio	$53.12M	0.89	N/A	N/A	$35.59 per share	0.14
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	5/12/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$45.54	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	5/7/2025 (Estimated)
CRGX CARGO Therapeutics	-$98.15M	-$3.72	N/A	N/A	N/A	N/A	-38.16%	-33.94%	5/13/2025 (Estimated)
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
BLUE bluebird bio	0.37	0.51	0.33
CRGX CARGO Therapeutics	N/A	18.94	18.95
TVGN Tevogen Bio	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
BLUE bluebird bio	87.43%
CRGX CARGO Therapeutics	93.16%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
BLUE bluebird bio	1.40%
CRGX CARGO Therapeutics	1.38%
TVGN Tevogen Bio	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
BLUE bluebird bio	520	9.72 million	9.59 million	Optionable
CRGX CARGO Therapeutics	116	46.05 million	45.39 million	N/A
TVGN Tevogen Bio	3	175.05 million	75.97 million	N/A

BLUE, TVGN, ACIU, and CRGX Headlines

Recent News About These Companies

Tevogen Bio appoints new head of government affairs

March 27, 2025 | uk.investing.com

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

March 26, 2025 | globenewswire.com

Tevogen Bio benoemt nieuwe directeur overheidsrelaties

March 26, 2025 | nl.investing.com

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

March 25, 2025 | globenewswire.com

Neal Flomenberg Sells 232,968 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

March 15, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 232,968 Shares

March 15, 2025 | insidertrades.com

Neal Flomenberg Sells 70,384 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

March 12, 2025 | marketbeat.com

Tevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

March 12, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $76,718.56 in Stock

March 12, 2025 | insidertrades.com

Tevogen Bio dient octrooi in voor T-cel-gerichte vaccintechnologie

March 11, 2025 | nl.investing.com

Tevogen announces new patent filed for T cell vaccine

March 11, 2025 | markets.businessinsider.com

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

March 10, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft

March 8, 2025 | insidermonkey.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $18,737.92 in Stock

March 8, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $97,370.90 in Stock

March 8, 2025 | marketbeat.com

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

March 7, 2025 | markets.businessinsider.com

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

March 7, 2025 | globenewswire.com

Tevogen Bio’s wetenschappelijk directeur verkoopt aandelen ter waarde van $ 250k

March 7, 2025 | nl.investing.com

Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells 14,639 Shares of Stock

March 7, 2025 | insidertrades.com

Tevogen Bio Inc: Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

March 4, 2025 | finanznachrichten.de

D. Boral Capital Initiates Coverage of Tevogen Bio Holdings (TVGN) with Buy Recommendation

March 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUE, TVGN, ACIU, and CRGX Company Descriptions

AC Immune NASDAQ:ACIU

$1.77 -0.11 (-5.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.82 +0.05 (+2.82%)

As of 05:08 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

bluebird bio NASDAQ:BLUE

$4.89 -0.14 (-2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$4.87 -0.02 (-0.41%)

As of 07:26 PM Eastern

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CARGO Therapeutics NASDAQ:CRGX

$4.10 -0.13 (-3.07%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 0.00 (-0.12%)

As of 04:05 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Tevogen Bio NASDAQ:TVGN

$1.00 -0.07 (-6.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 +0.02 (+2.50%)

As of 06:57 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time